India, May 22 -- Biocon Biologics (BBL) announced that the Government of Malaysia has agreed to extend the current contract period of 36 months under the existing insulin supply agreement with its subsidiary in Malaysia, Biocon Sdn. Bhd., and Duopharma Marketing Sdn. Bhd. (DMktg), for an additional six (6) months effective from 29 April 2025 until 28 October 2025.Biocon Biologics has been the partner of choice for the Ministry of Health for its insulins requirement and has been serving patients in Malaysia for nearly 10 years. The company manufactures a range of recombinant human insulin products at its state- of- the- art facility in Johor, Malaysia. These insulin products are distributed in Malaysia through its commercial partner DMktg. T...